Cargando…

Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors

The Severe Acute Respiratory Syndrome (SARS) is a serious life-threatening and strikingly mortal respiratory illness caused by SARS-CoV. SARS-CoV which contains a chymotrypsin-like main protease analogous to that of the main picornavirus protease, 3CL(pro). 3CL(pro) plays a pivotal role in the viral...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wei, Zhu, He-Min, Niu, Guo-Jun, Shi, En-Zhi, Chen, Jie, Sun, Bo, Chen, Wei-Qiang, Zhou, Hong-Gang, Yang, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111328/
https://www.ncbi.nlm.nih.gov/pubmed/24316352
http://dx.doi.org/10.1016/j.bmc.2013.11.028
_version_ 1783513266276794368
author Liu, Wei
Zhu, He-Min
Niu, Guo-Jun
Shi, En-Zhi
Chen, Jie
Sun, Bo
Chen, Wei-Qiang
Zhou, Hong-Gang
Yang, Cheng
author_facet Liu, Wei
Zhu, He-Min
Niu, Guo-Jun
Shi, En-Zhi
Chen, Jie
Sun, Bo
Chen, Wei-Qiang
Zhou, Hong-Gang
Yang, Cheng
author_sort Liu, Wei
collection PubMed
description The Severe Acute Respiratory Syndrome (SARS) is a serious life-threatening and strikingly mortal respiratory illness caused by SARS-CoV. SARS-CoV which contains a chymotrypsin-like main protease analogous to that of the main picornavirus protease, 3CL(pro). 3CL(pro) plays a pivotal role in the viral replication cycle and is a potential target for SARS inhibitor development. A series of isatin derivatives as possible SARS-CoV 3CL(pro) inhibitors was designed, synthesized, and evaluated by in vitro protease assay using fluorogenic substrate peptide, in which several showed potent inhibition against the 3CL(pro). Structure–activity relationship was analyzed, and possible binding interaction modes were proposed by molecular docking studies. Among all compounds, 8k(1) showed most potent inhibitory activity against 3CL(pro) (IC(50) = 1.04 μM). These results indicated that these inhibitors could be potentially developed into anti-SARS drugs.
format Online
Article
Text
id pubmed-7111328
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71113282020-04-02 Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors Liu, Wei Zhu, He-Min Niu, Guo-Jun Shi, En-Zhi Chen, Jie Sun, Bo Chen, Wei-Qiang Zhou, Hong-Gang Yang, Cheng Bioorg Med Chem Article The Severe Acute Respiratory Syndrome (SARS) is a serious life-threatening and strikingly mortal respiratory illness caused by SARS-CoV. SARS-CoV which contains a chymotrypsin-like main protease analogous to that of the main picornavirus protease, 3CL(pro). 3CL(pro) plays a pivotal role in the viral replication cycle and is a potential target for SARS inhibitor development. A series of isatin derivatives as possible SARS-CoV 3CL(pro) inhibitors was designed, synthesized, and evaluated by in vitro protease assay using fluorogenic substrate peptide, in which several showed potent inhibition against the 3CL(pro). Structure–activity relationship was analyzed, and possible binding interaction modes were proposed by molecular docking studies. Among all compounds, 8k(1) showed most potent inhibitory activity against 3CL(pro) (IC(50) = 1.04 μM). These results indicated that these inhibitors could be potentially developed into anti-SARS drugs. Elsevier Ltd. 2014-01-01 2013-11-21 /pmc/articles/PMC7111328/ /pubmed/24316352 http://dx.doi.org/10.1016/j.bmc.2013.11.028 Text en Copyright © 2013 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Liu, Wei
Zhu, He-Min
Niu, Guo-Jun
Shi, En-Zhi
Chen, Jie
Sun, Bo
Chen, Wei-Qiang
Zhou, Hong-Gang
Yang, Cheng
Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors
title Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors
title_full Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors
title_fullStr Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors
title_full_unstemmed Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors
title_short Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors
title_sort synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as sars-cov 3c-like protease inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111328/
https://www.ncbi.nlm.nih.gov/pubmed/24316352
http://dx.doi.org/10.1016/j.bmc.2013.11.028
work_keys_str_mv AT liuwei synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors
AT zhuhemin synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors
AT niuguojun synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors
AT shienzhi synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors
AT chenjie synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors
AT sunbo synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors
AT chenweiqiang synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors
AT zhouhonggang synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors
AT yangcheng synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors